upneeq
Generic: oxymetazoline hydrochloride·Code: RVL-1201
upneeq: sourced relationships with 1 company · 1 FDA decision.
upneeq evidence translation
What we can confirm
1 FDA record
What it means
Source-backed records connect upneeq to RVLP; that link alone does not prove the drug works.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
How could upneeq → RVLP affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
acquired blepharoptosis
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| RVL Pharmaceuticals plc (RVLP) acquired blepharoptosis | Approved |
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with upneeq?
upneeq has dated SEC/FDA relationship records for RVL Pharmaceuticals plc.
What is upneeq's latest FDA decision?
The most recent tracked FDA decision for upneeq is Approval for 1 INDICATIONS AND USAGE UPNEEQ is indicated for the treatment of acquired blepharoptosis in adults. UPNEEQ is indicated for the treatment of acquired blepharoptosis in adults. ( 1 ), dated July 8, 2020.